


Stock Options (Right to Buy)	\$ 108.49	07/06/2020		M			21,502	(11)	08/07/2022	Common Stock	21,502	\$ 0	18,486	D
Stock Options (Right to Buy)	\$ 108.49	07/07/2020		M			2,577	(11)	08/07/2022	Common Stock	2,577	\$ 0	15,909	D
Stock Options (Right to Buy)	\$ 106.59							(11)	08/18/2023	Common Stock	30,400		30,400	D
Stock Options (Right to Buy)	\$ 106.59							(12)	08/18/2023	Common Stock	40,533		40,533	D
Restricted Stock Units	(10)							(13)	(13)	Common Stock	4,438		4,438	D
Stock Options (Right to Buy)	\$ 125.05							(13)	08/09/2024	Common Stock	24,460		24,460	D
Stock Options (Right to Buy)	\$ 125.05							(14)	08/09/2024	Common Stock	32,613		32,613	D
Restricted Stock Units	(10)							(15)	(15)	Common Stock	3,383		3,383	D
Stock Options (Right to Buy)	\$ 177.32							(15)	08/08/2025	Common Stock	18,066		18,066	D
Stock Options (Right to Buy)	\$ 177.32							(16)	08/08/2025	Common Stock	24,089		24,089	D
Restricted Stock Units	(10)							(17)	(17)	Common Stock	3,938		3,938	D
Stock Options (Right to Buy)	\$ 190.41							(17)	08/07/2026	Common Stock	19,936		19,936	D
Stock Options (Right to Buy)	\$ 190.41							(18)	08/07/2026	Common Stock	26,581		26,581	D

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hippel James 614 MCKINLEY PLACE N.E. MINNEAPOLIS, MN 55413			Chief Financial Officer	

Signatures

/s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.		07/08/2020
		Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$270.0000 to \$270.9800, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$271.0000 to \$271.9900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$272.0100 to \$272.9500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$273.2300 to \$274.2200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$274.2700 to \$275.0300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$270.0700 to \$271.0500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$271.0700 to \$271.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$272.0900 to \$272.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(9) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

(10) Fully exercisable.

(11) Options to purchase 10,134 shares vest on 8/18/2017 and options to purchase 10,133 shares vest on each of 8/18/2018, 8/18/2019 and 8/18/2020.

(12) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(13) Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021.

(14) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(15) Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.

(16) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(17) Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.